CGTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cognition Therapeutics Inc (CGTX) is not a strong buy at this time for a beginner investor with a long-term strategy. While the company has ongoing clinical trials and plans to meet with the FDA, its financial performance is weak, with significant losses and no revenue growth. Additionally, technical indicators do not suggest a strong entry point, and there are no proprietary trading signals to support immediate action. Holding off for clearer positive signals or improved fundamentals is advisable.
The MACD is slightly positive but contracting, RSI is neutral at 45.428, and moving averages are converging, indicating no clear trend. The stock is trading near its support level of 1.043, with resistance at 1.173. Overall, the technical indicators suggest a neutral stance.
The company has completed enrollment in a key Alzheimer's trial and plans to meet with the FDA in mid-2026 to discuss its drug development pipeline. Additionally, it reported a smaller-than-expected EPS loss, beating expectations by $0.07.
is down, which could weigh on sentiment.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income drop of -57.37% YoY, and an EPS decline of -77.78% YoY. The operating loss was significant at $47.799 million, and the company had $37 million in cash as of December 31, 2025.
No recent analyst rating or price target changes were provided. Wall Street sentiment is unclear, but the lack of significant hedge fund or insider trading activity suggests limited confidence in the stock at this time.
